SCHEMBL5195350

SCHEMBL5195350

COc1ccc(CCN2CCCCC2CC(N)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.56
TRPV6 Q9H1D0 1/20 0.54
SIGMAR1 Q99720 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
OPRD1 P41143 1/20 0.45
CHRM3 P20309 1/20 0.44
DRD2 P14416 1/20 0.44
SPHK2 Q9NRA0 2/20 0.44
SPHK1 Q9NYA1 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5195704 0.88 SPHK2 (0.52) SIGMAR1ALDH1A1SPHK2
SCHEMBL5193849 0.86 HRH3 (0.60) HRH3SIGMAR1DRD2
SCHEMBL5191198 0.86 MAPK1 (0.56) SIGMAR1ALDH1A1TSHRKMT2ACHRM3
SCHEMBL5193949 0.84 OPRD1 (0.45) HRH3SIGMAR1KMT2AOPRD1SPHK2
SCHEMBL6807045 0.84 HRH3 (0.63) HRH3TRPV6SIGMAR1SPHK2SPHK1
SCHEMBL6807049 0.84 HRH3 (0.63) HRH3TRPV6SIGMAR1SPHK2SPHK1
SCHEMBL9372352 0.84 HRH3 (0.63) HRH3TRPV6SIGMAR1SPHK2SPHK1
SCHEMBL15173715 0.83 HRH3 (0.59) HRH3TRPV6SIGMAR1ALDH1A1TSHR
SCHEMBL9374317 0.80 HRH3 (0.68) HRH3TRPV6SIGMAR1SPHK2SPHK1
SCHEMBL9372055 0.80 HRH3 (0.68) HRH3TRPV6SIGMAR1SPHK2SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0968206-B8 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX INC (US) 2007-01-24 EP disclosed
EP-0968206-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2000-01-05 EP disclosed
WO-1998037079-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 1998-08-27 WO disclosed